Acute Kidney Injury Following Autoimmune Hemolytic Anemia Due to Simultaneous Use of Ciprofloxacin and Hydrochlorothiazide: A Case Report and Review of The Literature Publisher



Yaghoubi F¹ ; Tavakoli F¹ ; Dalil D² ; Jamaloo H² Show Affiliations
Source: Rheumatology and Autoimmunity Published:2023

Abstract

Introduction: Rare cases of autoimmune hemolytic anemia (AHA) associated with using ciprofloxacin or hydrochlorothiazide (HCTZ) alone have been reported before. However, simultaneous use of both drugs could lead to a severe clinical condition. This study presents the combination of acute kidney injury (AKI) and AHA following the simultaneous use of ciprofloxacin and HCTZ for three days. Case Description: A 42-year-old Iranian woman presented to the emergency department with symptoms of fatigue, lethargy, nausea and vomiting, ataxia, oliguria, dark urine, and jaundice. The patient reported using HCTZ due to high blood pressure and ciprofloxacin for a urinary tract infection three days before presentation. Early laboratory findings revealed hemolytic anemia with a hemoglobin of 7 g/dl, the strongly positive direct and indirect Coombs test, high level of lactate dehydrogenase (820 IU/L), and hyperbilirubinemia (total: 3 mg/dL and direct: 1.2 mg/dL). Furthermore, hyperkalemia (5.2 mEq/L), hyperphosphatemia (6.2 mg/dL), high levels of BUN (100 mg/dL), and creatinine rise (6.8 mg/dL) were found. Urine analysis showed 2+ blood, 4-6 red blood cells, and cola-colored urine. Based on the findings, drug-induced AHA, followed by AKI, was diagnosed. Following, the drugs were stopped and steroid therapy was initiated. The patient underwent four sessions of hemodialysis to improve the AKI. Conclusion: Healthcare providers should be aware of the life-threatening adverse effects of commonly used drugs such as ciprofloxacin or HCTZ. The timely diagnosis of the offending drugs leads to avoiding the persistence of the risk factor and the deterioration of the patient's clinical condition. © 2023 The Authors. Rheumatology & Autoimmunity published by John Wiley & Sons Ltd on behalf of Chinese Medical Association.